- Patients
- Clinical Research
- Clinical trials
- DESTINY-05
2024-06-26T13:39:56.519Z
DESTINY - 05
DESTINY - 05
Breast cancer
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Breast Cancer
Study Phase
III
Trial Identifiers
NCT04622319
GenesisCare Location(s)
GenesisCare: North Shore
Principal Investigator(s)
Dr Sally Baron-Hay